anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sodium Phosphates Injection, USP, 3 mmol/mL (millimoles/mL), is a sterile, nonpyrogenic, concentrated solution containing a mixture of monobasic sodium phosphate and dibasic sodium phosphate in Water for Injection. 

The solution is administered after dilution by the intravenous route as an electrolyte replenisher. It must not be administered undiluted. 

Each mL contains: Monobasic sodium phosphate, monohydrate, 276 mg; dibasic sodium phosphate, anhydrous, 142 mg (equivalent to dibasic sodium phosphate, heptahydrate, 268 mg); Water for Injection q.s. In the 5 mL and 15 mL product, phosphoric acid and/or NaOH may have been added for pH adjustment. 

Each mL provides 3 mmol of phosphorus and 4 mEq sodium. It contains no bacteriostat, antimicrobial agent or added buffer. The pH is 5.7 (approx.). The osmolar concentration is 7 mOsmol/mL (calc.) 

The solution is intended as an alternative to potassium phosphate to provide phosphate ion (PO 43-) for addition to large volume infusion fluids for intravenous use. 

Sodium Phosphates, USP, monohydrate monobasic is chemically designated NaH 2PO 4 • H 2O. Occurs as white, odorless crystals or granules freely soluble in water. 

Dibasic Sodium Phosphate, USP, anhydrous, is chemically designated Na 2HPO 4. Occurs as a colorless or white granular salt freely soluble in water.
This group consisted of patients with generalized stage III periodontitis, who had interproximal CAL≥5 mm and PD≥6 mm as well as radiographical bone loss extending to the mid-third of the root or beyond at 30% of the teeth or more. CAL was not caused by trauma-related gingival recession, dental caries extending into the cervical areas of the teeth, endodontic lesions draining through the marginal periodontium, and the distal bone loss in adjacent second molars due to extractions of third molars. They showed no more than four teeth loss due to periodontitis.
The 23-item Substance Use Risk Profile Scale (SURPS) will be used to identify high-risk adolescents who enter the intervention trial. Adolescents who score high on one of SURPS subscales (i.e., high-risk youth) will be invited to participate in two group-based intervention sessions which target their dominant personality profile. The criterion for high scores on SURPS personality traits are determined based on norms from high-risk adolescents in the same age range who participated in previous trials on personality-targeted interventions.
Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
Patients with suspect Brugada Syndrome will be asked to undergo flecainide infusion (2 mg/Kg up to 150 mg maximum dose) over 10 minutes and their ECG will be continuously monitored. The objective of the study is to investigate if they show conversion from type 2 or type 3 ECG to a diagnostic type 1 ECG.
* Please refer to amoxicillin and clarithromycin full prescribing information for CONTRAINDICATIONS and WARNINGS, and for information regarding dosing in elderly and renally-impaired patients. 

† Controlled studies did not extend beyond indicated duration. 

‡ For patients who do not heal with lansoprazole delayed-release capsules for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis, an additional 8 week course of lansoprazole delayed-release capsules may be considered. 

§The lansoprazole delayed-release capsules dose was increased (up to 30 mg twice daily) in some pediatric patients after 2 or more weeks of treatment if they remained symptomatic. For pediatric patients unable to swallow an intact capsule please see Administration Options. 

¶ Varies with individual patient. Recommended adult starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Dosages up to 90 mg twice daily have been administered. Daily dose of greater than 120 mg should be administered in divided doses. Some patients with Zollinger-Ellison Syndrome have been treated continuously with lansoprazole delayed-release capsules for more than 4 years. 

# Controlled studies did not extend beyond 12 months 

Patients should be instructed that if a dose is missed, it should be taken as soon as possible. However, if the next scheduled dose is due, the patient should not take the missed dose, and should be instructed to take the next dose on time. Patients should be instructed not to take 2 doses at one time to make up for a missed dose.
The present invention provides an effective conditioning shampoo composition which is free of conditioning amounts of silicone conditioning agents. It comprises: A) about 5 % to about 40 % of a detersive surfactant mixture of an anionic detergent and an amphoteric surfactant, the weight ratio of the anionic detergent to the amphoteric surfactant being in the range of about 10:1 to 0.8:1; B) about 0.05 % to about 6 % of a conditioning agent selected from the group consisting of 0.05 % to 5 % of a complex of essentially equimolar amounts of a C8-C18 (EtO)1-10 carboxylic acid, and a C8C18 alkyl (EtO)0-10 dimethyl amine; 0.05 % to 1.0 % of a polyquaternary compound selected from the group consisting of a quaternized cellulosic polymer and a mixture of the quaternized cellulosic polymer with a non-cellulosic quaternary conditioning polymer; and mixtures of the foregoing; C) 0.1 % to 1 % of a static control mixture of a quaternary ammonium salt having the formula R9, R10, R11, R12 N+X- wherein R¿9? is a C14-C18 alkyl, R10 and R11 are each a C1-C4 alkyl, R12 is C1-C4 alkyl or benzyl and X?-¿ is a salt forming cation selected from the group consisting of chloride, bromide, methosulfate and ethosulfate; and a diquaternary ammonium salt having the formula (R¿13?)2R14R15N?+X-¿ wherein R¿13? is a C14-C18 alkyl or alkylene group and R14 and R15 are each a C1-C4 alkyl group or a (CH2CH20)nH group with at least one of R14 and R15 being a (CH2CH20)nH group, n is an integer from 2 to 20 and X is a cation as set forth above, the weight ratio of the monoalkyl quaternary salt to dialkyl quaternary salt being from about 1:4 to 4:1; and D) an aqueous medium. These compositions exhibit enhanced antistatic properties as compared to the same compositions containing either the monoalkyl quaternary salt or the dialkyl quaternary salt as the sole antistatic ingredient.
Children and adults with MTC and MEN2B, other non-tumor manifestations of MEN2, and patients with MEN2 who do not demonstrate MTC. Characterize the biology and manifestations of their disease.
PURPOSE:The titled improving agent, containing an extract of crude drugs consisting of Astragali Radix, Cinnamomi Cortex, Rehmanniae Radix, etc. with water or an aqueous solvent as an active constituent, and capable of inhibiting the lipolytic action of cancerous toxins (toxohormone L) having the lipolytic action. CONSTITUTION:An improving agent for cancerous symptoms prepared by extracting one or two or more crude drugs selected from Astragali Radix, Cinnamomi Cortex, Rehmaniae Radix, Poeny root, Cnidium, Atractylodes, Japanese angelica root, Ginseng, Hoelen and Licorice with water or an aqueous solvent, e.g. aqueous ethanol, filtering the resultant extract solution, drying the resultant filtrate by spray sdrying, freeze-drying, etc., and using the resultant powder directly or adding an excipient, assistant thereto, formulating the resultant mixture into a dosage form of a powder, granule, tablet, capsule, etc. The resultant improving agent is capable of improving the lipid metabolism and asitia of patients with cancers. The above-mentioned extraction is preferably carried out at room temperature or under heating at 80-100 deg.C.
The invention discloses a health care medicine pillow. The health care medicine pillow comprises a pillow interior and a pillowcase. The pillow interior is filled with medicines including tamarind pulp, wild pepper, mappianthus iodoies, clerodendranthus spicatus, camphor tree leaves, semen cassiae, blumea balsamifera, rauwolfia, tailed spicebush leaves, oroxylum indicum, scoliid nests, common gendarussa herb, symplocos paniculata, whiteflower leadword roots, cassia twigs, acorus tatarinowii, ricepaperplant pith, saposhnikovia leaves and Pu'er tea leaves. The invention further discloses a making method of the medicine pillow. Nearly twenty pure natural plant original medicines are adopted as the filling materials of the pillow interior of the health care medicine pillow, various chronic diseases and difficult miscellaneous diseases can be treated in an external dosing mode, diseases of patients can be treated in sleep, the treatment method is easy and convenient to perform, and no toxic and side effects will be caused to the human body. It proves that after the patients use the health care medicine pillow throughout the year, the chronic diseases such as hyperostosis, stroke sequela, insomnia, amnesia, dizziness, cervical vertebra diseases, intermittent headaches and cerebral circulation insufficiency can be well treated to help the patients nurse their health and rehabilitate.
The objective of this study is to investigate key prognostic factors of clinical data and prognostic factors in patients with hypertensive intracerebral hemorrhage (HICH) who have undergone neuroendoscopic hematoma evacuation, specifically focusing on those with a hemorrhage volume of 20-40 mL, to identify the determinants influencing their prognosis. In this study, a total of 113 patients were ultimately included in the analysis. Variables such as age, preoperative Glasgow Coma Scale (GCS) scores, and hemorrhage locations were assessed. LASSO logistic regression was employed to select pertinent variables, which were then incorporated into a multivariate logistic regression model. The model's performance was evaluated using ROC and calibration curves, along with clinical utility curves, and the recovery times of patients were analyzed using Kaplan-Meier curves, complemented by COX regression analysis. These three variables-Age (OR: 0.811; 95% CI 0.711-0.925), GCS score (OR: 25.923; 95% CI 4.108-163.598), and ICH location (OR: 7.345; 95% CI 1.811-29.783)-are strong predictors of intracerebral hemorrhage prognosis. Among the patients analyzed, 85.84% experienced a favorable prognosis. Younger age, higher preoperative GCS scores, and hemorrhages located in the basal ganglia and cerebral lobes were associated with better outcomes (mRS score of 0-3) . The nomogram, validated by an ROC curve analysis yielding an AUC of 0.9417 and the Hosmer-Lemeshow test, demonstrated accurate predictive and calibration capabilities for postoperative prognosis in patients with hypertensive intracerebral hemorrhage. Kaplan-Meier intervals and COX regression analysis indicated that age is a significant factor affecting the recovery time of these patients. Age, GCS score, and ICH location are significant prognostic factors for patients undergoing neuroendoscopic hematoma evacuation following hypertensive intracerebral hemorrhage, with age being a particularly important determinant of recovery time. Younger age, higher GCS scores, and lobar hemorrhage are associated with better prognosis.
A method and system for generating a patient specific anatomical heart model is disclosed. Volumetric image data, such as computed tomography (CT), echocardiography, or magnetic resonance (MR) image data of a patient's cardiac region is received. Individual models for multiple heart components, such as the left ventricle (LV) endocardium, LV epicardium, right ventricle (RV), left atrium (LA), right atrium (RA), mitral valve, aortic valve, aorta, and pulmonary trunk, are estimated in said volumetric cardiac image data. A multi-component patient specific anatomical heart model is generated by integrating the individual models for each of the heart components. Fluid Structure Interaction (FSI) simulations are performed on the patient specific anatomical model, and patient specific clinical parameters are extracted based on the patient specific heart model and the FSI simulations. Disease progression modeling and risk stratification are performed based on the patient specific clinical parameters.
Participants will undergo two months of Serlopitant 5mg daily per oral, followed by one month of washout. After the washout period, all participants were invited to participate in an open-label extension study with serlopitant 5 mg daily. The duration of the open-label extension study was either 12 months (for those who enrolled before May 2020) or 3 months (for those who registered after May 2020) due to drug availability.
Melanoma is the most dangerous skin cancer accounting for the highest skin cancer deaths. The prognosis for metastatic melanoma has improved considerably in recent years thanks to advances in the field of immunotherapy. The development of molecules blocking certain immunological "checkpoints" (checkpoints exerted by the CTLA-4 (Cytotoxic T lymphocytes Associated protein 4) and PD-1 (Programmed cell Death protein 1) has made it possible to obtain a significant improvement of the overall survival (OS) of patients treated for metastatic melanoma. Ipilimumab, an antibody blocking CTLA-4, is the first immunotherapy marketed, demonstrating for the first time a therapeutic response, however in a small number of patients (10 to 15%) and with significant toxicity (25% of grade 3-4). Subsequently, a second generation of more effective checkpoint blockers (30 to 40% good response) and less toxic, anti-PD-1 antibodies (pembrolizumab and nivolumab), quickly obtained a marketing authorization in the first line treatment of metastatic melanoma treatment and recently in an adjuvant situation after lymph node dissection in order to limit the risk of recurrence. However, despite these advances, a certain number of patients do not respond to treatment and it remains difficult to predict this therapeutic response. Furthermore, patients treated with ICI often experience cutaneous immune-related adverse events manifesting as skin rash, dermatitis, epidermal necrolysis, and in some cases as vitiligo like depigmentation of the skin, testifying to the development of a specific immunogenicity towards the melanocytes, cells causing melanoma, and responsible for a discoloration of the skin. Several studies have reported that a modification of certain bacteria in the digestive microbiota was predictive of the antitumor response to immunotherapy, while others were predictive of the appearance of significant autoimmune ICI-related toxicities (colitis). Several phase 1 studies have evaluated the impact of taking probiotics or fecal transplants on the tumor response of patients receiving immunotherapy for cancer (NCT 03819296; NCT03817125; NCT03643289). Thus by these new concepts, it would be interesting to assess the composition of the skin microbiota in patients treated with anti-PD-1 immunotherapy for the management of metastatic melanoma and developing during their follow-up vitiligo; predictive side effect of improved survival. These data will be compared to those obtained from patients with common vitiligo. This will be examined in patients skin swabs sampled at lesional and non-lesional sites. Functionally, we will characterize the microbial pathways using shotgun sequencing of microbial genomes and meta-transcriptomics (RNA sequencing of microbial communities of the skin).
General - If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Information for patients - Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis and Impairment of Fertility - Long-term studies in animals have not been performed to evaluate carcinogenic potential.

PREGNANCY: Category C. Animal reproduction studies have not been conducted with Sodium Sulfacetamide 9% - Sulfur 4.5% Wash. It is not known whether Sodium Sulfacetamide 9% - Sulfur 4% Wash can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide 9% - Sulfur 4.5% Wash should be given to a pregnant woman only if clearly needed.

NURSING MOTHERS: It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sodium Sulfacetamide 9% - Sulfur 4.5% Wash. However, small amounts of orally administered sulfonamides have been reported to be excreted in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide 9% - Sulfur 4.5% Wash is administered to a nursing woman.

PEDIATRIC USE: Safety and effectiveness in children under the age of 12 have not been established.
BACKGROUND: The causality between frailty and gestational diabetes mellitus (GDM) has not yet been fully explored. A potential bidirectional causality was also needed to be confirmed.
METHODS: A bidirectional two-sample Mendelian randomization (MR) was conducted, with frailty-related data was collected from UK Biobank and TwinGen and GDM-related data was collected from the FinnGen consortium. We performed univariable and multivariable-adjusted MR with adjustments for body mass index (BMI). Several methodologies of MR were conducted to confirm the robustness of results.
RESULTS: Frailty was significantly associated with elevated risks of GDM (OR, 3.563; 95% CI, 1.737 to 7.309; P< 0.001) and GDM was also significantly associated with elevated risks of frailty ( β , 0.087; 95% CI, 0.040 to 0.133; P< 0.001). There is no evidence demonstrating the existence of horizontal pleiotropy and heterogeneity. This association was robust after adjustments for BMI. The sensitivity analyses with Weighted median, Maximum likelihood, Penalised weighted median, MR Egger and MR PRESSO methods indicated consistent results.
CONCLUSION: Our study provides evidence of the bidirectional causal association between frailty and GDM from genetic perspectives, signaling that the identification and assessment of frailty should become a standard strategy during the early stages and care of gestational diabetes.
BACKGROUND: Previous studies reported varyingly positive, negative, or no relationships between caries and periodontitis. Therefore, the aim was to assess the potential co-occurrence of caries experience and periodontal inflammation on the same teeth.
METHODS: This cross-sectional study used data from the Lithuanian National Oral Health Survey. The study included a stratified random sample of 1405 individuals aged 34-78, recruited from 5 Lithuanian cities and 10 peri-urban/rural areas (response rate 52%). Information about sociodemographic (age, sex, education, residence), behavioral (sugar-containing diet, tooth brushing frequency, use of interdental care products, last dental visit, smoking) and biological (systemic disease, use of medication and xerostomia) determinants was collected using the World Health Organization (WHO) Oral Health Questionnaire for Adults supplemented with additional questions. Clinical data were recorded using the WHO criteria and collected by one trained and calibrated examiner. Dental caries status was recorded as sound, decayed, missing, filled surfaces. Subsequently for the analyses, status was recorded at a tooth-level as decayed- and filled-teeth (DT and FT) including proximal, buccal, and oral surfaces. Two measures were used for periodontal status. The probing pocket depth (PPD) was measured at six sites and recorded at a tooth level into the absence of PPD or presence of PPD ≥ 4 mm. Bleeding on probing (BOP) was measured at the same six sites and was recorded as either present or absent at a tooth-level. Univariable and multivariable 2-level random intercept binary logistic regression analyses were utilized.
RESULTS: Positive associations were found between DT and BOP (OR 1.42, 95% CI 1.20-1.67), FT and BOP (OR 2.07, 95% CI 1.82-2.23), DT and PPD (OR 1.38, 95% CI 1.15-1.67) and FT and PPD (OR 2.01, 95% CI 1.83-2.20).
CONCLUSIONS: Our findings add evidence for the co-occurrence of periodontal inflammation and caries on the same teeth. This suggests the need for increased emphasis on a transdisciplinary approach in designing oral health interventions that target dental caries and periodontal disease simultaneously. In addition, longitudinal studies exploring the co-occurrence of caries and periodontal disease at the same sites, taking into consideration the levels of both conditions and genetic variation, are warranted.
Endoluminally delivered tissue patches and related systems and methods for delivering the tissue patches for treating lesions of the alimentary tract are disclosed. A tissue patch includes a substrate, a tissue implant attached to the substrate, and a protective liner covering at least a portion of the tissue implant. A method includes providing a tissue patch having a tissue implant attached to a substrate and a protective liner covering at least a portion of the tissue implant. The tissue patch is formed into a contracted state and inserted into a lumen containing the lesion. The tissue patch then is positioned in the vicinity of the lesion. After removing the protective liner to reveal the tissue implant, the tissue implant is placed in the lesion.
Study design, size, duration: : prospective randomized controlled clinical trial 50 patients with endometriosis diagnosed by US prepared for ICSI were enrolled in the study after consent. they were randomized into 2 groups 25 received antioxidants before starting the protocol , 25 did not receive . randomization was done by closed envelop single blind for patient Participants/materials, setting, methods: was done in the Egyptian centre for IVF from March 2013 to October 2013 . 50 patients with endometriosis diagnosed by US prepared for ICSI were enrolled in the study after consent. they were randomized into 2 groups 25 received antioxidants before starting the protocol , 25 did not receive . all patients were subjected to plasma sample before start long protocol for induction and second on day of ovum pick up . embryo transfer was done according to embryo grading .
Patients undergo standard radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.